Cardiosense
CHICAGO, Illinois, United States · Health Care
Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.
Key facts
- Headquarters
- CHICAGO, Illinois, United States
- Employees
- 38
- Industries
- Health Care
- Status
- Private
- Website
- cardiosense.com
- Company page
Recent activity at Cardiosense
Cardiosense funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $26.1M |
| Dec 2022 | Venture | $9.1M |
| Dec 2022 | Series A | $15.1M |
Leadership
- John Martin, Chief Medical Officer
Verified email and direct lines for Cardiosense’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Cardiosense files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Cardiosense in the news
- FDA Grants De Novo Status to Cardiosense PCWP Software for HFrEF - HCPLive (May 27, 2026)
- Cardiosense wins FDA clearance for wearable heart monitor - MedTech Dive (Jul 31, 2025)
- Cardiosense wins FDA Clearance for wearable heart monitor, CardioTag - Medical Economics (Jul 30, 2025)
- Cardiosense Presents New Clinical Analysis of SEISMIC-HF I Data on AI-Enabled Volume Assessment in Heart Failure at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 Scientific Symposium - Business Wire (Oct 28, 2025)
- Cardiosense, Inc., Completes $15.1 Million Series A Financing to Advance Artificial Intelligence Platform for Heart Disease - PR Newswire (Dec 08, 2022)
- Device, Paving the Way for Advanced Cardiac Function Monitoring - Business Wire (Jul 30, 2025)
- Cardiosense receives FDA Breakthrough Device designation for algorithm to identify patients at risk of decompensated heart failure - PR Newswire (Feb 15, 2022)
- Cardiosense Presents New Analysis of the SEISMIC-HF I Study Validating its AI Algorithm for Noninvasive PCWP Assessment at the American Heart Association's 2025 Scientific Sessions - Business Wire (Nov 06, 2025)
Companies similar to Cardiosense
- Candel Therapeutics · Health Care
- CPTx · Health Care
- Larada Sciences dba Lice Clinics of America · Health Care
- GC Therapeutics · Health Care
- Panda Health · Health Care
About Cardiosense: questions and answers
What does Cardiosense do?
Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.
Where is Cardiosense headquartered?
Cardiosense is headquartered in CHICAGO, Illinois, United States.
How many employees does Cardiosense have?
Cardiosense has about 38 employees.
Has Cardiosense raised funding?
Yes. Fundz has recorded 3 funding events for Cardiosense. The most recent, $26.1M, was in Aug 2026.
What is the latest news on Cardiosense?
On Aug 24, 2026, Cardiosense
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy